Spots Global Cancer Trial Database for osteosarcoma
Every month we try and update this database with for osteosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | NCT05235165 | Metastatic Mali... Metastatic Oste... Osteosarcoma | Biospecimen Col... Computed Tomogr... Questionnaire A... Thoracoscopy Thoracotomy | - 50 Years | Children's Oncology Group | |
| Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study | NCT04546243 | Osteosarcoma Me... Pulmonary Disea... Resectable Sarc... Survival | resection group radiotherapy gr... | - | Peking University People's Hospital | |
| Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors | NCT01661400 | Glioma Neuroectodermal... Wilms Tumor Rhabdomyosarcom... Sarcoma, Ewing Osteosarcoma Retinoblastoma | Metronomic Cycl... Thalidomide | 6 Months - 21 Years | Washington University School of Medicine | |
| A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma | NCT01002092 | Osteosarcoma | Chemotherapy Endostar | 12 Years - 60 Years | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd | |
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma | NCT03359018 | Progression-fre... Overall Surviva... Clinical Benefi... Toxicity | Apatinib SHR-1210 | 11 Years - | Peking University People's Hospital | |
| SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | NCT04803877 | Osteosarcoma Osteosarcoma in... Osteosarcoma Re... Osteosarcoma Me... | Regorafenib 40 ... Regorafenib 20M... Nivolumab | 5 Years - | Sarcoma Alliance for Research through Collaboration | |
| Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | NCT06235125 | Osteosarcoma Pulmonary Metas... Fluorescence Metastatic Sarc... Pediatrics | Cytalux | 6 Years - 17 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In- Vitro Study | NCT05801887 | Osteosarcoma | Extracorporeal ... No ESWT | - | Krishnadevaraya College of Dental Sciences & Hospital | |
| Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | NCT01674101 | Osteosarcoma Ewing's Sarcoma Rhabdomyosarcom... Synovial Sarcom... Malignant Perip... Malignant Fibro... Chondrosarcoma ... | Endurance Strengthening Stretching Home exercise p... | 6 Years - 30 Years | St. Jude Children's Research Hospital | |
| Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy | NCT03742193 | Osteosarcoma Pulmonary Metas... Apatinib | Apatinib GD regimen | 10 Years - 50 Years | Ruijin Hospital | |
| A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma | NCT04833582 | Osteosarcoma | ZN-c3 Gemcitabine | 12 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | NCT00667342 | Osteosarcoma Malignant Fibro... | Bevacizumab Cisplatin Doxorubicin Methotrexate Ifosfamide etoposide Surgery Radiotherapy | - 30 Years | St. Jude Children's Research Hospital | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Huntsman Biopsy Study | NCT00615329 | Soft Tissue Sar... Osteosarcoma | - | State University of New York - Upstate Medical University | ||
| Epigenetic Biomarker for Osteosarcoma | NCT03336554 | Histologic Resp... Objective Respo... Progression-fre... Overall Surviva... | 10 Years - | Peking University People's Hospital | ||
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Clinical Evaluation for Sarcoma Originated From Bone | NCT03358992 | Sensitivity Specificity Histological Re... Survival | - | Peking University People's Hospital | ||
| Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | NCT05588648 | Osteosarcoma | Vactosertib | 14 Years - | MedPacto, Inc. | |
| Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma | NCT00899275 | Osteosarcoma | Cytology Specim... | - | Children's Oncology Group | |
| A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors | NCT00001209 | Neuroectodermal... Neuroepitheliom... Osteosarcoma Sarcoma Sarcoma, Ewing'... | vincristine, ad... | - | National Institutes of Health Clinical Center (CC) | |
| Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma | NCT00899275 | Osteosarcoma | Cytology Specim... | - | Children's Oncology Group | |
| Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | NCT03860207 | Neuroblastoma Osteosarcoma Other Solid Tum... | Humanized 3F8 B... Blood draw | 1 Year - 17 Years | Y-mAbs Therapeutics | |
| Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | NCT02711007 | Osteosarcoma Metastasis | apatinib | 16 Years - | Peking University People's Hospital | |
| Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | NCT05210374 | Relapsed Sarcom... | Disulfiram Copper Gluconat... Liposomal Doxor... | 1 Year - | Case Comprehensive Cancer Center | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| HGS-ETR2 to Treat Children With Solid Tumors | NCT00428272 | Ewing's Sarcoma Osteosarcoma Neuroblastoma Rhabdomyosarcom... | Lexatumumab alo... Lexatumumab in ... Interferon gamm... Gamma 1b potent... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| The Prognostic Value of Serum Biomarkers in Osteosarcoma | NCT05093101 | Osteosarcoma | case series rev... | 2 Years - | Istituto Ortopedico Rizzoli | |
| European Study in Bone Sarcoma Patients Over 40 Years | NCT02986503 | Spindle Cell Sa... Osteosarcoma | Doxorubicin+cis... Doxorubicin+cis... | 41 Years - 65 Years | Italian Sarcoma Group | |
| Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | NCT01336803 | Bone Cancer Chondrosarcoma Ewing's Sarcoma Osteosarcoma Rhabdomyosarcom... Bone Necrosis Bone Sarcoma Osteomyelitis | Feraheme Magnetic Resona... | 10 Years - 21 Years | Stanford University | |
| Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | NCT00631631 | Osteosarcoma | Mifamurtide (L-... | 2 Years - 50 Years | Millennium Pharmaceuticals, Inc. | |
| Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study | NCT04546243 | Osteosarcoma Me... Pulmonary Disea... Resectable Sarc... Survival | resection group radiotherapy gr... | - | Peking University People's Hospital | |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | NCT00026780 | Ewing Sarcoma Osteosarcoma Neuroblastoma Acute Lymphobla... Neurofibromatos... | - 35 Years | National Institutes of Health Clinical Center (CC) | ||
| Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma | NCT01807143 | Osteosarcoma | laboratory biom... | - | Children's Oncology Group | |
| Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma | NCT04571229 | Osteosarcoma | L-MTP-PE | - | Memorial Sloan Kettering Cancer Center | |
| Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma | NCT01650090 | Pulmonary Relap... | Inhaled Lipid C... | 13 Years - | Eleison Pharmaceuticals LLC. | |
| Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery | NCT05779670 | Osteosarcoma Ewing Sarcoma Chondrosarcoma Bone Tumor | 12 Years - 90 Years | Istituto Ortopedico Rizzoli | ||
| Diffusion Study on Patients With Osteosarcoma | NCT01615640 | Osteosarcoma | - | Klinikum Stuttgart | ||
| Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma | NCT04294511 | Osteosarcoma | Camrelizumab in... | 14 Years - 65 Years | Sun Yat-sen University | |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | NCT03373097 | Neuroblastoma Neuroblastoma R... GD2-positive So... Osteosarcoma Ewing Sarcoma Sarcoma | GD2-CART01 | 12 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| Huntsman Biopsy Study | NCT00615329 | Soft Tissue Sar... Osteosarcoma | - | State University of New York - Upstate Medical University | ||
| Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS | NCT03997747 | Osteosarcoma | cytology specim... | 12 Years - | Peking University People's Hospital | |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | NCT04154189 | Osteosarcoma | Lenvatinib Ifosfamide Etoposide Lenvatinib | 2 Years - 25 Years | Eisai Inc. | |
| Surveillance Study of Patients With Newly Diagnosed Osteosarcoma | NCT01194284 | Osteosarcoma | Mifamurtide | 2 Years - 40 Years | Takeda | |
| A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy | NCT01758666 | Osteosarcoma | Methotrexate,Ca... | 12 Years - 60 Years | Tianjin Medical University Cancer Institute and Hospital | |
| DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers | NCT01139983 | Sarcoma | DNA analysis RNA analysis fluorescence in... microarray anal... polymerase chai... reverse transcr... laboratory biom... | - | Children's Oncology Group | |
| Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: | NCT00615628 | Osteosarcoma Paget's Disease | - | State University of New York - Upstate Medical University | ||
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | NCT02536183 | Pediatric Cance... Solid Tumors Rhabdomyosarcom... Ewing Sarcoma Soft Tissue Sar... Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor... | Magnetic resona... Lyso-thermosens... | - 30 Years | Children's National Research Institute | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Upfront Surgical Resection for Osteosarcoma | NCT06384404 | Osteosarcoma | Questionnaire | 5 Years - 40 Years | Montefiore Medical Center | |
| Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy | NCT01848457 | Osteosarcoma Nephrotoxicity Ototoxicity | Pantoprazole High-dose metho... | - 30 Years | Children's Hospital of Philadelphia | |
| Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy | NCT00673179 | Osteosarcoma | Doxorubicin Cisplatin Methotrexate Leucovorin Dexrazoxane Ifosfamide Questionnaire Gemcitabine Sargramostim Surgery Mesna | 5 Years - 40 Years | M.D. Anderson Cancer Center | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities | NCT04383288 | Osteosarcoma | 12 Years - 30 Years | Grupo Espanol de Investigacion en Sarcomas | ||
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | NCT02013336 | Recurrent or Re... Ewing Sarcoma Rhabdomyosarcom... Neuroblastoma Osteosarcoma | MM-398 (Irinote... | 12 Months - 20 Years | South Plains Oncology Consortium | |
| Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study | NCT00001217 | Osteosarcoma | pre-surgical ch... | - | National Institutes of Health Clinical Center (CC) | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab | NCT03919539 | Drug Resistance... Biomarkers for ... | 5hmc testing | 12 Years - | Peking University People's Hospital | |
| PD-L1 Expression in Advanced Osteosarcoma | NCT03582527 | Progression Survival | all study parti... | - | Peking University People's Hospital | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma | NCT04824352 | Effect of Drug Toxicity, Drug | apatinib | 12 Years - 70 Years | Peking University People's Hospital | |
| A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma | NCT01002092 | Osteosarcoma | Chemotherapy Endostar | 12 Years - 60 Years | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | NCT06171282 | Osteosarcoma Sarcoma Soft Tissue Sar... Bone Tumor | Recombinant onc... | 16 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma | NCT05194605 | Osteosarcoma | Prediction mode... | - | West China Hospital | |
| Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients | NCT03643133 | Osteosarcoma | Mifamurtide EI or M-API reg... | - 50 Years | UNICANCER | |
| High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma | NCT00634322 | Osteosarcoma | glucarpidase leucovorin | 8 Years - 50 Years | BTG International Inc. | |
| Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | NCT04040205 | Chondrosarcoma Osteosarcoma Soft Tissue Sar... | Abemaciclib | 18 Years - | Medical College of Wisconsin | |
| Donor Site Morbidity After Free Vascularized Fibular Graft | NCT06324916 | Osteosarcoma | Xray | 18 Years - | Assiut University | |
| High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma | NCT00634322 | Osteosarcoma | glucarpidase leucovorin | 8 Years - 50 Years | BTG International Inc. | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma | NCT00689195 | Osteosarcoma | Curcumin powder Ashwagandha ext... | 8 Years - 65 Years | Tata Memorial Hospital | |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | NCT04698785 | Bone Sarcoma Osteosarcoma | Treatment by re... Treatment by pl... | 12 Years - | Centre Leon Berard | |
| Donor Site Morbidity After Free Vascularized Fibular Graft | NCT06324916 | Osteosarcoma | Xray | 18 Years - | Assiut University | |
| MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | NCT02076906 | Relapsed Pediat... Refractory Pedi... Rhabdomyosarcom... Ewing Sarcoma Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor Desmoid Tumor | Magnetic Resona... | - 30 Years | Children's National Research Institute | |
| A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | NCT04886765 | Osteosarcoma | ALMB-0168 | 16 Years - | AlaMab Therapeutics (Shanghai) Inc. | |
| Upfront Surgical Resection for Osteosarcoma | NCT06384404 | Osteosarcoma | Questionnaire | 5 Years - 40 Years | Montefiore Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
